Table 1.
Summary of Demographic and Clinical Characteristics for Eyes with MNV Secondary to Myopic Macular Degeneration (MMD) and Eyes with MNV Secondary to Age-Related Macular Degeneration (AMD)
| MMD (n=30 Eyes; 25 Subjects) | AMD (n=45 Eyes; 41 Subjects) | p-value | ||
|---|---|---|---|---|
| Male (%) | 3/25 (12) | 15/41 (37) | 0.030 | |
| Age (years) | 55±19 | 75±8 | <0.001 | |
| Racial/Ethnic background | Asian (%) | 2/25 (8) | 0/41 (0) | 0.002 |
| Hispanic or Latino (%) | 5/25 (20) | 0/41 (0) | ||
| White (%) | 17/25 (68) | 38/41 (93) | ||
| Undeclared (%) | 1/25 (4) | 3/41 (7) | ||
| Systemic blood pressure | Systolic (mm Hg) | 131±25 | 131±15 | 0.998 |
| Diastolic (mmHg) | 75±11 | 74±10 | 0.883 | |
| Smoking status | Current | 1/25 (4) | 2/41 (5) | 0.118 |
| Never | 18/25 (72) | 19/41 (46) | ||
| Former | 6/25 (24) | 20/41 (49) | ||
| Body-mass index | 26.3±5.0 | 28.4±5.0 | 0.145 | |
| LogMAR BCVA | 0.31±0.35 (~20/40) | 0.30±0.26 (~20/40) | 0.954 | |
| Spherical equivalent (diopter) | −12.51±5.09 | +0.55±1.59 | <0.001 | |
| Previous PDT | 3/30 (10) | 2/45 (4) | 0.345 | |
| Number of prior anti-VEGF injections | 5±7 | 14±11 | <0.001 | |
| Time since last injection (months) | 27±36 | 4±9 | 0.002 | |
| Treatment naive | 3/30 (10) | 7/45 (16) | 0.488 | |
| Treated with: | Aflibercept | 6/30 (20) | 20/45 (44) | 0.066 |
| Bevacizumab | 14/30 (47) | 8/45 (18) | ||
| Ranibizumab | 6/30 (20) | 8/45 (18) | ||
| Not specified | 1/30 (3) | 3/45 (7) | ||
| Actively getting IVI therapy (%) | 11/30 (37) | 32/45 (71) | 0.003 | |
| Intraocular pressure (mm Hg) | 16.2±3.4 | 15.7±3.4 | 0.545 | |
| Lens status | Phakic | 23/30 (77) | 23/45 (51) | 0.026 |
| Pseudophakic | 7/30 (23) | 22/45 (49) | ||
Notes: The data is presented as mean ± standard deviation where applicable. The data in parentheses is presented as a percentage (%), and significant p-values (<0.05) are highlighted in bold.